Another study involving melanoma and NSCLC clinical data found the cut‐off to be 192 NSM, with 74% sensitivity and 59.3% specificity.8 In this study, more than 20% of patients with LUSC, other subtypes of lung carcinoma, hepatocellular carcinoma, glioma, esophageal carcinoma, and CRC had NSM counts above 192, indicating that TMB‐H may be a good indicator for the use of PD‐1/PD‐L1 blockade. Here, CD274 is linked to glioma.